School of Medicine, Tsinghua University, Beijing, China.
Air Force Medical Center PLA, Beijing, China.
Trials. 2023 Sep 11;24(1):580. doi: 10.1186/s13063-023-07595-4.
Spinal cord stimulation (SCS) is a surgical technique used in patients with chronic intractable pain, and its effectiveness and safety have been validated by multiple studies. However, to maintain an optimal and steady long-term effect is still challenging. Here, we report a new management paradigm integrating smartphone application and remote programming. Chronic pain patients with SCS implants can monitor their pain status on the phone and change stimulation parameters accordingly. The PreMaSy study is a randomized controlled trial to evaluate the clinical effectiveness and safety of this precise management system.
Patients with chronic intractable pain will be screened for eligibility, and 82 participants are anticipated to be enrolled in this trial. After the electrode implantation, the stimulation effectiveness will be tested. Participants with a reduction of more than 50% in the visual analog scale (VAS) will receive implantation of an implantable pulse generator and randomized (1:1) into the experimental group or control group. All participants will be asked to take online follow-ups and complete assessments using a smartphone application. Daily pain characteristic assessments and monthly quality of life questionnaires are integrated into the App, and participants will be required to complete these assessments. The daily VAS for pain intensity will be monitored and a threshold will be set based on baseline VAS score. The interventional appointment will be scheduled once the threshold is reached. The primary outcome is the health condition and quality of life assessed by the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). Utility values of EQ-5D-5L will be assessed at baseline and 1, 3, and 6 months post-operative.
The PreMaSy study aims to evaluate the effectiveness and safety of a novel App-based, patient-centered, self-assessment management system for chronic intractable pain. A randomized controlled trial is designed to test the non-inferiority of this precise management system compared to the monthly online follow-ups. It is also expected to yield valuable experiences regarding precision medicine.
ClinicalTrials.gov NCT05761392. Registered on March 07, 2023.
脊髓刺激(SCS)是一种用于慢性难治性疼痛患者的手术技术,其有效性和安全性已被多项研究证实。然而,维持一个最佳和稳定的长期效果仍然具有挑战性。在这里,我们报告了一种新的管理模式,将智能手机应用和远程编程相结合。带有 SCS 植入物的慢性疼痛患者可以在手机上监测自己的疼痛状况,并相应地改变刺激参数。PreMaSy 研究是一项随机对照试验,旨在评估这种精确管理系统的临床效果和安全性。
将对慢性难治性疼痛患者进行筛选,预计将有 82 名参与者参加这项试验。在电极植入后,将测试刺激的有效性。接受视觉模拟量表(VAS)降低超过 50%的患者将接受可植入脉冲发生器的植入,并随机(1:1)分为实验组或对照组。所有参与者将被要求通过智能手机应用进行在线随访和完成评估。每日疼痛特征评估和每月生活质量问卷已集成到应用程序中,参与者将被要求完成这些评估。将监测每日 VAS 疼痛强度,并根据基线 VAS 评分设置一个阈值。一旦达到阈值,就会安排干预预约。主要结局是使用五维健康量表(EQ-5D-5L)评估的健康状况和生活质量。EQ-5D-5L 的效用值将在基线和术后 1、3 和 6 个月进行评估。
PreMaSy 研究旨在评估一种新型基于应用程序、以患者为中心、自我评估的慢性难治性疼痛管理系统的有效性和安全性。一项随机对照试验旨在测试这种精确管理系统与每月在线随访相比的非劣效性。预计也将获得有关精准医学的宝贵经验。
ClinicalTrials.gov NCT05761392。注册于 2023 年 3 月 7 日。